OncoImmunology is a leading peer-reviewed journal published by Taylor & Francis Inc, dedicated to advancing the understanding of the dynamic interplay between the immune system and cancer. Established in 2012 and adopting an open access model since 2020, OncoImmunology provides a platform for high-quality research disseminated globally, with a notable focus on innovative therapies and immunotherapeutic strategies aimed at improving patient outcomes. The journal boasts an impressive impact in the field, holding Q1 rankings in both Immunology and Oncology categories for 2023, and it is recognized within the top-tier journals in its domain, reflected in its Scopus ranks and percentiles. With contributions from leading experts and a wide audience of researchers, clinicians, and advanced students, OncoImmunology not only facilitates scholarly dialogue but also addresses pivotal challenges in cancer treatment, making it an essential resource for those invested in the future of oncological and immunological research.

IMUNOLOGY AND CELL BIOLOGY, published by Wiley, serves as a prominent platform for disseminating cutting-edge research in the fields of immunology and cell biology. With an ISSN of 0818-9641 and an E-ISSN of 1440-1711, this journal has established itself since its inception in 1987, demonstrating a commitment to advancing knowledge in its disciplines through high-quality articles. Renowned for its rigorous peer-review process, it holds a Q2 quartile ranking in both immunology and cell biology categories as of 2023, showing its competitive stature in these fields. IMUNOLOGY AND CELL BIOLOGY is indexed among the elite journals worldwide, with impressive Scopus rankings, including a rank of #75/233 in Immunology and Allergy. The journal’s comprehensive scope ensures that it caters to an audience of researchers, professionals, and students who are dedicated to exploring the intricate mechanisms of immune responses and cellular interactions. Although it does not operate under an open access model, its subscription-based content remains invaluable for those seeking to broaden their understanding of immunology and cell biology. By providing a forum for significant scientific dialogue, IMUNOLOGY AND CELL BIOLOGY continues to shape the future of research in these vital areas.

Immunopharmacology and Immunotoxicology, published by Taylor & Francis Ltd, is a distinguished academic journal with a focus on the interrelation between pharmacology, immunology, and toxicology. Established in 1978, the journal serves as a vital platform for the dissemination of cutting-edge research aimed at enhancing the understanding of immunologically mediated drug responses and toxic effects. The journal encompasses a broad scope of topics relevant to the fields of immunology, pharmacology, and toxicology, offering insights that are pivotal for both academia and the pharmaceutical industry. With a commendable 2023 impact factor and ranking in Q3 in Immunology and Q2 in both Pharmacology and Toxicology, it holds a respected position within its categories, making it a valuable resource for researchers, professionals, and students seeking to stay abreast of the latest developments in the field. The journal is accessible through traditional subscription models and encourages submissions that bring forth innovative findings that might influence therapeutic strategies and public health.

Journal of Immunology Research, published by HINDAWI LTD, stands as a pivotal open-access journal in the realm of immunology, with a particular emphasis on advancing knowledge in both fundamental and applied aspects of the field. Since its inception in 1990, the journal has committed to the dissemination of high-quality research, earning a respectable impact factor that reflects its significance. Based in Egypt, it provides a platform for researchers from around the world, showcasing innovative studies and reviews that contribute to the understanding of immune system mechanisms. Its 2023 rankings place it in the Q2 category for Immunology and Allergy, and Q1 in the broader category of Medicine (miscellaneous), indicating a strong reputation among its peers. Through its open-access model, the journal promotes wide accessibility of cutting-edge research, catering to researchers, professionals, and students alike. With ambitions that converge through 2024, the Journal of Immunology Research continues to be an essential resource for those seeking to explore the forefront of immunological science.

HEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.

Journal of Immunotoxicology, published by Taylor & Francis Ltd, is at the forefront of research in the intersecting fields of immunology and toxicology. With an annual impact factor that reflects its growing influence, this Open Access journal has been essential for disseminating valuable knowledge since its inception in 2004. The journal welcomes novel research articles, reviews, and commentary that explore the effects of xenobiotics on the immune system, contributing to a deeper understanding of immunotoxicological mechanisms and implications for human health. As a recognized platform, it has achieved commendable rankings in Scopus, positioning it within Q3 in Immunology and Q2 in Toxicology categories as of 2023. This ensures that the journal remains a critical resource for researchers, professionals, and students seeking to advance their knowledge and contribute to the evolving landscape of immunotoxicology. With an Open Access model since 2017, it maximizes accessibility and reaches a global audience, supporting the collaborative efforts needed to address contemporary challenges in health and safety.

Journal for ImmunoTherapy of Cancer, published by the esteemed BMJ Publishing Group, is a leading scholarly journal dedicated to advancing the field of immuno-oncology. Since its inception in 2013, this Open Access journal has emerged as a pivotal platform for disseminating cutting-edge research and innovative methodologies in cancer immunotherapy. With a remarkable impact factor and stellar rankings, including Q1 listings in multiple relevant categories such as Cancer Research, Immunology, and Molecular Medicine, it plays a crucial role in bridging the gap between basic immunology and clinical applications, thus fostering collaboration among researchers, healthcare professionals, and students. The journal's scope encompasses a diverse range of topics, focusing on the latest breakthroughs and experimental findings in cancer treatment, making it indispensable for those seeking to contribute to the evolving landscape of oncological sciences. Located in the United Kingdom at the British Medical Association House, the journal continues to serve as a valuable resource for those at the forefront of cancer research and therapy.

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

MELANOMA RESEARCH is a leading journal dedicated to the exploration and dissemination of innovative research in the field of melanoma and skin cancers. Published by Lippincott Williams & Wilkins, this journal has been a pivotal resource since its inception in 1991, continually evolving to encompass significant advancements within dermatology and oncology through 2024. With a focus on high-quality, peer-reviewed articles, it offers critical insights into cellular mechanisms, treatment strategies, and emerging therapies pertinent to melanoma. It currently holds a Q3 category in Cancer Research and a Q2 category in Dermatology, while also ranking within the 65th percentile for Medicine Dermatology according to Scopus. Although not an open-access journal, MELANOMA RESEARCH ensures accessibility through various institutional subscriptions, making it an invaluable asset for researchers, professionals, and students engaged in pioneering melanoma research.

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.